Every material Form 8-K Polaryx Therapeutics, Inc. has filed with the SEC since July 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S., as its Chief Medical Officer, effective September 1, 2026, ahead of the planned SOTERIA Phase 2 trial start in the fourth quarter of 2026. The filing describes his prior roles as Chief Medical Officer at Spruce Biosciences and senior clinical development executive at Tyra Biosciences, and the company says his experience supports its clinical leadership. The filing contains no financial results or guidance, so the appointment is a leadership change rather than a change in reported performance.
Will Charlton, M.D., M.A.S., appointed Chief Medical Officer effective September 1, 2026; appointment announced August 27, 2026 and disclosed in a press release dated September 1, 2026
Previously Senior Vice President, Clinical Development, Skeletal Dysplasia at Tyra Biosciences (March 2025 to June 2026) and Chief Medical Officer at Spruce Biosciences (March 2022 to January 2025)
Company plans to initiate the SOTERIA Phase 2 trial of lead candidate PLX-200 in the fourth quarter of 2026; the company received an FDA safe to proceed letter in October 2025
Polaryx Therapeutics said its Chief Medical Officer, Lisa Bollinger, MD, resigned on July 19, 2026, effective immediately. The company said the departure is not expected to affect previously disclosed clinical timelines, regulatory plans or development strategy, and it has started searching for a successor.
Lisa Bollinger, MD, resigned as Chief Medical Officer on July 19, 2026, effective immediately
Company does not anticipate effects on previously disclosed clinical timelines, regulatory plans or development strategy
Responsibilities will be assumed by existing leadership team members in the interim
Polaryx Therapeutics' board set its 2026 Annual Meeting of Stockholders to be held virtually on September 10, 2026, with a July 27, 2026 record date. The filing also sets a July 27, 2026 deadline for stockholder proposals and director nominations to be considered for the proxy materials, because the company held no annual meeting in 2025.
Annual Meeting to be held virtually on September 10, 2026
Stockholders of record at close of business on July 27, 2026 may vote
Deadline for stockholder proposals and director nominations for proxy inclusion is close of business on July 27, 2026
Company may change the record date, meeting date and location before the meeting
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Polaryx Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →